Relative replication fitness of efavirenz-resistant mutants of HIV-1: Correlation with frequency during clinical therapy and evidence of compensation for the reduced fitness of K103N + L100I by the nucleoside resistance mutation L74V

Virology

Volumn 353, Issue 1, 2006, Pages 184-192

  Koval, Christine E ^a   Dykes, Carrie ^a   Wang, Jiong ^a   Demeter, Lisa M ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

Efavirenz; HIV_1; K103N; L100I; P225H; Replication fitness; V108I

Indexed keywords

EFAVIRENZ; NUCLEOSIDE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ARTICLE; ASSAY; CELL LINE; CONTROLLED STUDY; CORRELATION ANALYSIS; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOTHESIS; NONHUMAN; PRIORITY JOURNAL; TREATMENT FAILURE; VIROGENESIS; VIRUS ISOLATION; VIRUS MUTANT; VIRUS REPLICATION;

ANTI-HIV AGENTS; CELL LINE; DRUG RESISTANCE, VIRAL; GENES, VIRAL; HIV INFECTIONS; HIV-1; HUMANS; MUTATION; OXAZINES; RNA-DIRECTED DNA POLYMERASE; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 33747888022     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2006.05.021     Document Type: Article

References (30)

1. Ait-Khaled M., Rakik A., Griffin P., Stone C., Richards N., Thomas D., Falloon J., and Tisdale M. HIV-1 reverse transcriptase and protease resistance mutations selected during 16-72 weeks of therapy in isolates from antiretroviral therapy-experienced patients receiving abacavir/efavirenz/amprenavir in the CNA2007 study. Antivir. Ther. 8 2 (2003) 111-120
2. Archer R.H., Dykes C., Gerondelis P., Lloyd A., Fay P., Reichman R.C., Bambara R.A., and Demeter L.M. Mutants of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase resistant to nonnucleoside reverse transcriptase inhibitors demonstrate altered rates of RNase H cleavage that correlate with HIV-1 replication fitness in cell culture. J. Virol. 74 18 (2000) 8390-8401
3. Bacheler L.T., Anton E.D., Kudish P., Baker D., Bunville J., Krakowski K., Bolling L., Aujay M., Wang X.V., Ellis D., Becker M.F., Lasut A.L., George H.J., Spalding D.R., Hollis G., and Abremski K. Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy. Antimicrob. Agents Chemother. 44 9 (2000) 2475-2484
4. Bacheler L., Jeffrey S., Hanna G., D'Aquila R., Wallace L., Logue K., Cordova B., Hertogs K., Larder B., Buckery R., Baker D., Gallagher K., Scarnati H., Tritch R., and Rizzo C. Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy. J. Virol. 75 11 (2001) 4999-5008
5. Back N.K., Nijhuis M., Keulen W., Boucher C.A., Oude Essink B.O., van Kuilenburg A.B., van Gennip A.H., and Berkhout B. Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme. EMBO J. 15 15 (1996) 4040-4049
6. Boyer P.L., Gao H.Q., and Hughes S.H. A mutation at position 190 of human immunodeficiency virus type 1 reverse transcriptase interacts with mutations at positions 74 and 75 via the template primer. Antimicrob. Agents Chemother. 42 2 (1998) 447-452
7. Byrnes V.W., Emini E.A., Schleif W.A., Condra J.H., Schneider C.L., Long W.J., Wolfgang J.A., Graham D.J., Gotlib L., Schlabach A.J., et al. Susceptibilities of human immunodeficiency virus type 1 enzyme and viral variants expressing multiple resistance-engendering amino acid substitutions to reserve transcriptase inhibitors. Antimicrob. Agents Chemother. 38 6 (1994) 1404-1407
8. Chou T.C., and Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 22 (1984) 27-55
9. Coffin J.M. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 267 (1995) 483-489
10. Demeter L., DeGruttola V., Lustgarten S., Eshleman S.H., Hammer S., Fischl M., and Squires K. A genotypic score for efavirenz hypersusceptibility is associated with virologic response to efavirenz + indinavir +/- abacavir in nucleoside-experienced patients (ACTG 368). 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA (2004) Abstract #669
11. DHHS, 2005. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents.
12. Domaoal, R.A., Bambara, R.A., and Demeter, L.M., in press. HIV-1 reverse transcriptase mutants resistant to non-nucleoside reverse transcriptase inhibitors do not adversely affect DNA synthesis: pre-steady state and steady state kinetic studies. J. Acquired Immune Defic. Syndr.
13. Gerondelis P., Archer R.H., Palaniappan C., Reichman R.C., Fay P.J., Bambara R.A., and Demeter L.M. The P236L delavirdine-resistant human immunodeficiency virus type 1 mutant is replication defective and demonstrates alterations in both RNA 5′-end- and DNA 3′-end-directed RNase H activities. J. Virol. 73 7 (1999) 5803-5813
14. Holland J.J., de la Torre J.C., Clarke D.K., and Duarte E. Quantitation of relative fitness and great adaptability of clonal populations of RNA viruses. J. Virol. 65 6 (1991) 2960-2967
15. Hsiou Y., Ding J., Das K., Clark Jr. A.D., Boyer P.L., Lewi P., Janssen P.A., Kleim J.P., Rosner M., Hughes S.H., and Arnold E. The Lys103Asn mutation of HIV-1 RT: a novel mechanism of drug resistance. J. Mol. Biol. 309 2 (2001) 437-445
16. Huang W., Gamarnik A., Limoli K., Petropoulos C.J., and Whitcomb J.M. Amino acid substitutions at position 190 of human immunodeficiency virus type 1 reverse transcriptase increase susceptibility to delavirdine and impair virus replication. J. Virol. 77 2 (2003) 1512-1523
17. Japour A.J., Mayers D.L., Johnson V.A., Kuritzkes D.R., Beckett L.A., Arduino J.M., Lane J., Black R.J., Reichelderfer P.S., D'Aquila R.T., et al. Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. The RV-43 Study Group, the AIDS Clinical Trials Group Virology Committee Resistance Working Group. Antimicrob. Agents Chemother. 37 5 (1993) 1095-1101
18. Kleim J.P., Rosner M., Winkler I., Paessens A., Kirsch R., Hsiou Y., Arnold E., and Riess G. Selective pressure of a quinoxaline nonnucleoside inhibitor of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) on HIV-1 replication results in the emergence of nucleoside RT-inhibitor-specific (RT Leu-74->Val or Ile and Val-75->Leu or Ile) HIV-1 mutants. Proc. Natl. Acad. Sci. U. S. A. 93 1 (1996) 34-38
19. Larder B.A. 3′-Azido-3′-deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitors. Antimicrob. Agents Chemother. 36 12 (1992) 2664-2669
20. Larder B.A. Interactions between drug resistance mutations in human immunodeficiency virus type 1 reverse transcriptase. J. Gen. Virol. 75 Pt. 5 (1994) 951-957
21. Lu J., Sista P., Giguel F., Greenberg M., and Kuritzkes D.R. Relative replicative fitness of human immunodeficiency virus type 1 mutants resistant to enfuvirtide (T-20). J. Virol. 78 9 (2004) 4628-4637
22. Maree A.F., Keulen W., Boucher C.A., and De Boer R.J. Estimating relative fitness in viral competition experiments. J. Virol. 74 23 (2000) 11067-11072
23. Petropoulos C.J., Parkin N.T., Limoli K.L., Lie Y.S., Wrin T., Huang W., Tian H., Smith D., Winslow G.A., Capon D.J., and Whitcomb J.M. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 44 4 (2000) 920-928
24. Richman D.D., Havlir D., Corbeil J., Looney D., Ignacio C., Spector S.A., Sullivan J., Cheeseman S., Barringer K., Pauletti D., et al. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J. Virol. 68 3 (1994) 1660-1666
25. Selmi B., Deval J., Alvarez K., Boretto J., Sarfati S., Guerreiro C., and Canard B. The Y181C substitution in 3′-azido-3′-deoxythymidine-resistant human immunodeficiency virus, type 1, reverse transcriptase suppresses the ATP-mediated repair of the 3′-azido-3′-deoxythymidine 5′-monophosphate-terminated primer. J. Biol. Chem. 278 42 (2003) 40464-40472
26. Shulman N., Zolopa A.R., Passaro D., Shafer R.W., Huang W., Katzenstein D., Israelski D.M., Hellmann N., Petropoulos C., and Whitcomb J. Phenotypic hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in treatment-experienced HIV-infected patients: impact on virological response to efavirenz-based therapy. AIDS 15 9 (2001) 1125-1132
27. Shulman N.S., Bosch R.J., Mellors J.W., Albrecht M.A., and Katzenstein D.A. Genetic correlates of efavirenz hypersusceptibility. AIDS 18 13 (2004) 1781-1785
28. Wang J., Dykes C., Domaoal R.A., Koval C.E., Bambara R.A., and Demeter L.M. The HIV-1 reverse transcriptase mutants G190S and G190A, which confer resistance to non-nucleoside reverse transcriptase inhibitors, demonstrate reductions in RNase H activity and DNA synthesis from tRNA(Lys, 3) that correlate with reductions in replication efficiency. Virology 348 (2006) 462-474
29. Wu H., Huang Y., Dykes C., Liu D., Ma J., Perelson A.S., and Demeter L.M. Modeling and estimation of replication fitness of human immunodeficiency virus type 1 in vitro experiments by using a growth competition assay. J. Virol. 80 5 (2006) 2380-2389
30. Yeni P.G., Hammer S.M., Hirsch M.S., Saag M.S., Schechter M., Carpenter C.C., Fischl M.A., Gatell J.M., Gazzard B.G., Jacobsen D.M., Katzenstein D.A., Montaner J.S., Richman D.D., Schooley R.T., Thompson M.A., Vella S., and Volberding P.A. Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. JAMA 292 2 (2004) 251-265